NeonMind

[ad_1] Company Continues to Expand Its Scientific Expertise with Noted Expert in Utilizing Ketamine for Treatment Resistant Depression VANCOUVER, BC / ACCESSWIRE / September 22, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) (“NeonMind” or the “Company“), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight